Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Conventional treatments like chemotherapy and radiotherapy face challenges with toxicity and specificity.
• Photodynamic therapy (PDT) shows potential but is limited by poor tissue penetration and oxygen dependence.

Purpose of the Study:

• To review the mechanisms, advantages, and technological innovations of Near-infrared photoimmunotherapy (NIR-PIT).
• To highlight NIR-PIT's potential as a transformative therapeutic approach for lung cancer.

Main Methods:

• Utilizes antibody-photoabsorber conjugates (e.g., IRDye700DX-linked antibodies) for targeted cancer cell binding.
• Activates conjugates with 690-nm Near-infrared (NIR) light, inducing non-ROS-dependent cell death (photochemosis).
• Leverages advances in light-delivery devices for deep pulmonary lesion targeting.

Main Results:

• NIR-PIT demonstrates high specificity, overcoming PDT limitations.
• Induces immediate physical disruption of cancer cell membranes and robust immunogenic cell death.
• Promotes systemic antitumor immunity and allows for safe, repeated treatment cycles.
• Adaptable to various tumor targets, including EGFR and tumor microenvironment components.

Conclusions:

• NIR-PIT presents a promising, highly specific therapeutic strategy for lung cancer.
• Its unique mechanism and technological advancements position it as a potential game-changer in lung cancer treatment.